Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Riber Earnings Release 2011

Oct 18, 2011

1629_iss_2011-10-18_0b999b9a-d237-49f2-906c-acc8479a3b59.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Press release - Revenues at the end of September 2011 Bezons, October 18th, 2011 - 5:45 pm

Strong growth in revenues at the end of September

Bezons, October 18th, 2011 – 5:45 pm – RIBER, the global leader for molecular beam epitaxy (MBE), posted €18.5 million in revenues at the end of September 2011, up 142% in relation to the same period the previous year. Revenues for the third quarter of 2011 came to €5.5 million, compared with €3.2 million for the third quarter of 2010. With an order book of €19.3 million, RIBER is forecasting around €29 million in full-year revenues.

2011 2010 Change
Systems 5.7 2.8 +104%
Services and accessories 3.7 4.2 -12%
Cells and sources 9.1 0.6 x14
Total reported revenues 18.5 7.6 +142%
Total order book 19.3 19.1 +2%

Growth in business is being driven primarily by the increase in sales of evaporation sources, multiplied by 14 over one year. This performance reflects the delivery of major orders for investments on the OLED (Organic LED) flat screen markets.

During the first three quarters, 5 MBE systems were delivered, compared with four research systems at September 30th, 2010, with a marked improvement in their unit value.

However, the service business has contracted by 12% as a result of the slowdown in demand, particularly in the US.

At September 30th, 2011, the breakdown of RIBER's sales was as follows: Asia (55%), Europe (35%) and North America (10%).

2011 objectives revised upwards

The order book represented €19.3 million at the end of September 2011 (€19.1 million one year earlier), with three production systems and seven research systems, to be delivered between 2011 and 2013.

In view of the delivery schedule for the end of the year, RIBER is targeting around €29 million in annual revenues, combined with an operating margin rate of over 15%.

This outlook confirms the relevance of RIBER's strategic model, which is based on three profitable growth drivers:

  • Continuing to further strengthen RIBER's leadership on the market for molecular beam epitaxy machines;
  • Capitalizing on the installed base and growing sales of epitaxy equipment, spare parts and accessories, as well as the corresponding services;
  • Diversifying the business, releasing a range of high value-added equipment (cells and sources) on the market for strong-growth application fields (thin-layer solar cells, OLED lighting and screens, etc.).

2011 full-year revenues will be released on Tuesday January 17th, 2012 (after close of trading).

About RIBER:

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-tech equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED flat screens and new generation solar cells. Riber is listed on Euronext Paris Compartment "C" and is part of the CAC Small, CAC Mid & Small and CAC IT indexes.

ISIN: FR0000075954 Reuters code: RIBE.PA Bloomberg code: RIB: FP Riber has been innovation certified by OSEO, the dedicated French innovation agency, enabling it to qualify for French innovation mutual funds (FCPI).

RIBER CALYPTUS
Olivier Handschumacher Cyril Combe
tel: +33 1 39 96 65 00 tel: +33 1 53 65 68 68
[email protected] [email protected]

www.riber.com